Recent real-world study in community hospital setting reported amplicon-based NGS can provide genomic profiling results with a routine TAT of 3-days or less.
This study evaluated the feasibility of in-house fast NGS in a streamlined workflow at a community hospital on 578 consecutive solid tumor samples covering different cancer types, including lung cancer, melanoma, and colorectal carcinoma.
Genomic profiling in precision oncology is transforming cancer care. But long waiting periods for biomarker test results from the lab can delay treatment decisions.
Explore how fast in house genomic profiling changes the oncology patients journey and helps to improve their outcomes.
Democratization of NGS is the key to accelerating cancer care.
"Significantly shorter time to results enables faster and optimal treatment decisions."
"It improves care coordination between multidisciplinary teams, leading to true personalized medicine."
"Small sample requirement provides biopsy stewardship,
“tissue saving”."
"Allows for the development of local expertise in biomarker testing to support the future of precision medicine."
We've detected your location to be Japan.
Sorry, you cannot access this website. The content on www.oncomine.com is only intended for healthcare professionals. Formore information on our research solutions, please visit ThermoFisher.com
このウェブサイトは、日本国内の医療関係者の方への情報提供を目的としており、一般の方に対する情報提供を目的としたものではないことをご了承ください。研究用製品の情報はThermoFisher.comよりご覧ください。